On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.

On the news front, the company previously announced that its CLDN18.2-targeting antibody-drug conjugate CMG901, co-developed with AstraZeneca, achieved positive topline results in the global Phase III CLARITY-Gastric01 trial. The study demonstrated statistically significant overall survival improvement in second-line and beyond CLDN18.2-positive advanced gastric cancer patients versus investigator's choice, with a safety profile consistent with prior studies and no new safety signals identified. The company projects peak annual sales of USD 3-5 billion for the drug.

Despite the strongly positive clinical data, the stock has exhibited a classic sell-the-news pattern, declining 5.59% on July 28 when results were announced and continuing lower, suggesting the market had already priced in the expected outcome ahead of the readout.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)